Suppr超能文献

重症神经疾病患者强化与常规胰岛素治疗比较。

Intensive versus conventional insulin therapy in critically ill neurologic patients.

机构信息

Boston University School of Medicine, Boston, MA, USA.

出版信息

Neurocrit Care. 2010 Dec;13(3):299-306. doi: 10.1007/s12028-010-9417-3.

Abstract

BACKGROUND

Previous studies of glycemic control in non-neurologic ICU patients have shown conflicting results. The purpose was to investigate whether intensive insulin therapy (IIT) to keep blood glucose levels from 80 to 110 mg/dl or conventional treatment to keep levels less than 151 mg/dl was associated with a reduction of mortality and improved functional outcome in critically ill neurologic patients.

METHODS

Within 24 h of ICU admission, mechanically ventilated adult neurologic patients were enrolled after written informed consent and randomized to intensive or conventional control of blood glucose levels with insulin. Primary outcome measure was death within 3 months. Secondary outcome measures included 90-day modified Rankin scale (mRS) score, ICU, and hospital LOS.

RESULTS

81 patients were enrolled. The proportion of deaths was higher among IIT patients but this was not statistically significant (36 vs. 25%, P = 0.34). When good versus poor outcome at 3 months was dichotomized to mRS score 0-2 versus 3-6, respectively, there was no difference in outcome between the two groups (76.2 vs. 75% had a poor 3-month outcome, P = 1.0). There was also no difference in ICU or hospital LOS. Hypoglycemia (<60 mg/dl) and severe hypoglycemia (<40 mg/dl) were more common in the intensive arm (48 vs. 11%, P = 0.0006; and 4 vs. 0%, P = 0.5, respectively).

CONCLUSION

There was no benefit to IIT in this small critically ill neurologic population. This is the first glycemic control study to specifically examine both critically ill stroke and traumatic brain injury (TBI) patients and functional outcome. Given these results, IIT cannot be recommended over conventional control.

摘要

背景

先前对非神经科 ICU 患者血糖控制的研究结果相互矛盾。本研究旨在探讨将血糖水平维持在 80-110mg/dl 的强化胰岛素治疗(IIT)与将血糖水平维持在<151mg/dl 的常规治疗相比,是否与危重症神经科患者死亡率的降低和功能结局的改善相关。

方法

在 ICU 入住后 24 小时内,通过书面知情同意书,对接受机械通气的成年神经科患者进行入组,并随机分为强化或常规血糖控制胰岛素组。主要观察终点为 3 个月内的死亡。次要观察终点包括 90 天改良 Rankin 量表(mRS)评分、ICU 和住院 LOS。

结果

共纳入 81 例患者。IIT 组的死亡率较高,但差异无统计学意义(36%比 25%,P=0.34)。当将 3 个月时的良好与不良结局定义为 mRS 评分 0-2 与 3-6 时,两组之间的结局无差异(76.2%比 75%的患者 3 个月时的结局不良,P=1.0)。两组 ICU 和住院 LOS 也无差异。强化组低血糖(<60mg/dl)和严重低血糖(<40mg/dl)更为常见(48%比 11%,P=0.0006;4%比 0%,P=0.5)。

结论

在这个小的危重症神经科人群中,IIT 没有获益。这是首次专门针对重症卒中及创伤性脑损伤(TBI)患者进行血糖控制的研究,并对功能结局进行了评估。鉴于这些结果,不能推荐 IIT 替代常规治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验